AstraZeneca: FDA Grants Orphan Drug Designation To Eplontersen For Transthyretin Amyloidosis

AstraZeneca (AZN.L,AZN) reported that Eplontersen has been granted Orphan Drug Designation in the US for the treatment of transthyretin-mediated amyloidosis. Eplontersen is a ligand-conjugated antisense investigational medicine currently in phase III clinical trials for amyloid transthyretin cardiomyopathy and amyloid
transthyretin polyneuropathy.

eplontersen will be jointly developed and commercialized by Ionis and AstraZeneca in the US. Hereditary ATTR-PN is expected to be the first indication for which the
companies will seek regulatory approval for eplontersen, with the potential to
file a new drug application with the FDA by the end of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Asweets Global Inc. is recalling about 2,000 units of Wonder & Wise Activity Tables for potential risk of choking hazard to young children, a statement by the U.S. Consumer Product Safety Commission (CPSC) showed. The company said the screws of the tables can become loose and/or detach from the xylophone component of the activity tables to pose a choking hazard to young children. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday a net loss for the fourth quarter that sharply widened from last year, despite 9 percent growth in revenues, hurt by a decreases in the market prices of our equity investments in publicly-traded companies. Omni-channel fashion retailer Macy's, Inc. (M) reported Thursday a first-quarter net income of $286 million or $0.98 per share, sharply higher than $103 million or $0.32 per share in the prior-year quarter. Excluding items, adjusted net income for the quarter was $315 million or $1.08 per share, compared...
Follow RTT